A phase 2 study of the efficacy and safety of muvalaplin (LY3473329) in adults with elevated Lp(a) at high risk of cardiovascular (CV) events
Educational Partners and Supporters
AstraZeneca has provided a sponsorship grant towards this independent programme.
(Founding Partner)
Novartis has provided with arm’s length sponsorship towards the set-up of the Lp(a) Forum. The content was developed independently by the Forum.
